The difference between molotinib targeted drugs and chemotherapy drugs and their application in the treatment of myelofibrosis

Momelotinib, whose trade name is Ojjaara, is a therapeutic drug targeting a specific target, rather than a chemotherapy drug in the traditional sense. This innovative drug was developed by the British company GlaxoSmithKline (GSK) and was approved by the U.S. Food and Drug Administration (FDA) in September 2023. It is specially designed to treat anemia symptoms in adult patients with moderate or high-risk myelofibrosis (MF).

Myelofibrosis is a rare myeloproliferative disease characterized by the abnormal proliferation of fibrous tissue in the bone marrow and the decline of hematopoietic function. This can cause patients to develop a series of severe clinical symptoms, including anemia, thrombocytopenia, splenomegaly, etc. The advent of molotinib has brought new treatment hope to these patients who are suffering from the disease.

Compared with chemotherapy drugs, molotinib, as a targeted therapy drug, has higher selectivity and fewer side effects. Its mechanism of action is unique and precise. It mainly inhibits the activity of JAK1/JAK2 kinase and blocks the abnormal activation of JAK-STAT signaling pathway, thereby effectively treating primary myelofibrosis. In addition, molotinib can also target and inhibit the activity of ACVR1, a liver cell surface protein closely related to the control of hepcidin. By reducing the expression of hepcidin, molotinib can significantly improve the anemia symptoms associated with myelofibrosis.

Clinical trial data fully prove the significant efficacy of molotinib in improving patient symptoms, increasing blood transfusion independence, and improving anemia laboratory indicators. Compared with traditional chemotherapy drugs, molotinib has relatively few side effects, mainly including thrombocytopenia, bleeding, bacterial infection, fatigue, dizziness, diarrhea and nausea. These side effects are usually mild and tolerated by most patients.

Overall, molotinib, as an innovative targeted therapy, has demonstrated unique advantages and potential in the field of myelofibrosis treatment. It not only provides patients with new treatment options, but is also expected to significantly improve patients' quality of life and extend survival. Compared with traditional chemotherapy drugs, molotinib has higher selectivity and fewer side effects, bringing a safer and more effective treatment experience to patients with myelofibrosis.